Bonesupport Holding

Regulatory Filings • Nov 28, 2023

BONESUPPORT hosts Capital Markets Day 2023

BONESUPPORT HOLDING AB,(publ), a leading company in orthobiologics for the management of bone injuries, hosts its Capital Markets Day (CMD) for analysts, investors, and media today. The purpose is to give an update on the strategy and development of BONESUPPORT. Focus of the day is innovation. At the event the company is also giving an updated outlook for 2024 of sales growth above 40 percent.

As a consequence of the strong current business momentum and further initiatives coming into effect as of 2025, the company currently finds it prudent to apply a one-year guiding horizon. Thus, the updated guidance is;

Sales growth above 40 percent (in constant currency) in 2024.

The CMD will also give the participants a more in-depth understanding of BONESUPPORT's plans, including a future expansion into spinal fusion and a planned marketing authorization application submission for CERAMENT V in the US in Q1 2025.

The event is held at GT30 Grev Ture, rum Bond, Grev Turegatan 30 in Stockholm and is broadcast live today 13:30-17:00 pm CET at https://ir.financialhearings.com/bonesupport-cmd-2023 /register.

For more information contact:

BONESUPPORT Holding AB Emil Billbäck, CEO +46 (0) 46 286 53 70

Håkan Johansson, CFO +46 (0) 46 286 53 70 ir@bonesupport.com

Cord Communications Charlotte Stjerngren +46 (0) 708 76 87 87 charlotte.stjerngren@cordcom.se www.cordcom.se

This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-11-28 12:00 CET.

Press Release 28 November 2023 12:00:00 CET

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 329 million in 2022. Please visit www.bonesupport. com for more information.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

BONESUPPORT hosts Capital Markets Day 2023